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Building Confidence in the
Prescribing and Monitoring of
Pre-exposure Prophylaxis (PrEP)
in Vermont
Scott Neary, MS III
The Larner College of Medicine
Family Medicine Rotation, Milton Family Practice

Identifying the Problem
• Approximately 1.2 million people are at high risk of contracting HIV in the
United States
• Daily PrEP (Truvada) use can lower HIV contraction through anal sex by
90% and through IV drug use by 70%
• As of 2016 only 77,000 people were prescribed PrEP, a 73% increase from
2012
• 93% were men
• 64% were between 25-44 years old

• The rate of PrEP use is 2 times higher in the northeast than the rest of the
country, with a majority of those users in New York
• Vermont is aiming to have zero new transmission by 2020, and PrEP will be
important to reaching that goal

Barriers to prescribing PrEP in
Vermont
Survey completed in 2015 by the Larner College Medicine
found:
• 52% of providers in Vermont felt training was a barrier
• Long term safety of use and drug resistance were
significant concerns
• 47% of providers considered themselves “not confident
at all” when asked about having an informed discussion
about PrEP with patients
As of 2016:
• 671 persons are living with HIV/AIDS in Vermont
• Of these 69% were residents of Vermont at time of their
diagnosis
• Over 1/3 of persons diagnosed with HIV/AIDS in Vermont live
in Chittenden County

There were 8 new HIV diagnoses in Vermont in 2016

Public Health Cost
• The total lifetime treatment cost in the United
States for HIV infection based on diagnosis in
2009 was estimated to be $16.6 billion
• Vermont’s total lifetime treatment cost based
on diagnosis in 2009 was $4 million

• $379,668 lifetime cost per person diagnosed in 2009
with HIV

• Farnham et al. study estimated the medical
savings from prevention programs between
1991-2006 to be $129.9 billion
• 361,878 infections prevented

• Cash paying customers pay $1,758 for 30
tablets of Truvada, although most insurance
plans cover the cost.

Community Perspective
“If we truly want to get to our goal of zero new transmissions by 2020
we need to have a holistic approach, looking at prevention and
medications like PrEP”
• Taylor Small , Director of Health and Wellness at the Pride Center of Vermont

“I do feel we could use more sexual health and HIV prevention and
treatment in our residency. I am usually very upfront with my patients
to let them know that I may need to take some time to reference and
find more information for them, but that I am happy to do so as part of
my own learning, but also to take care of their needs.”
• Kelly Brooks, MD Chief Resident University of Vermont Family Medicine Residency

Intervention and Methodology
• An educational card was distributed to the
residents and attending physicians at a local
family medicine practice, inviting them to use the
information as a resource for prescribing and
monitoring patients on PrEP
• A copy of the card was placed in the teaching
area allowing easy access for providers
• The information card covered
indications/contraindications, side effects, and
necessary monitoring for patients on the
medication
• Recommendations from the CDC, reference
databases, and local LGBT+ outreach centers
were incorporated into the educational card

Results/Response
• Conversation with Providers who have received and reviewed the
information card felt the information would be helpful in their future
discussion with patients looking to use PrEP
• Effectiveness of the Information card will best be measured by
looking at the number of providers at the clinic that start prescribing
PrEP, and the overall number of patients that are prescribed PrEP
• Future results will also be shown by surveying the providers about
their confidence in prescribing PrEP after having time to utilize the
information on the card

Evaluation of Effectiveness/response
• The effectiveness of the intervention would be evaluated by surveying
providers at the clinic to determine their confidence level with
prescribing and monitoring patients on PrEP, and by evaluating how
helpful they perceived the flyer to be
• The effectiveness would also be gauged evaluation of patient charts,
seeing if there was an increased frequency of discussion and
prescription of PrEP after the implementation of the flyer

Recommendations for future projects
• Talking with the Family Medicine Residents, there is a lack of formal
training in recognizing patients who would benefit from PrEP and how
to initiate that conversation with patients.
• Future projects could create a formal training for residents, including
simulation to help broach the topic with patients

• Looking to see what barriers patients have initiating the discussion of
PrEP with their providers
• Future projects could evaluate how effective educational flyers are
long term, and if the information is continually referenced and
updated
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